US equities
|
SPCX
$167.12
▲+5.13%
NVDA
$236.30
▲+1.01%
MU
$1,064.31
▼-0.98%
TSLA
$378.74
▲+2.20%
MSFT
$525.03
▲+1.45%
SNDK
$1,709.43
▼-0.61%
INTC
$117.32
▼-1.68%
META
$744.27
▲+2.22%
SPCX
$167.12
▲+5.13%
NVDA
$236.30
▲+1.01%
MU
$1,064.31
▼-0.98%
TSLA
$378.74
▲+2.20%
MSFT
$525.03
▲+1.45%
SNDK
$1,709.43
▼-0.61%
INTC
$117.32
▼-1.68%
META
$744.27
▲+2.22%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
RxSight, Inc. - Common Stock
(NQ:
RXST
)
4.745
+0.065 (+1.39%)
Delayed Quote
Updated: 12:25 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RxSight, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
August 26, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight (RXST) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Alcon partnership revenue offsets 19% product sales decline from competitive pressure.
Via
The Motley Fool
Topics
Earnings
RxSight Q2 Earnings Call Highlights
↗
August 06, 2026
RxSight (NASDAQ:RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026...
Via
MarketBeat
Topics
Earnings
RxSight (NASDAQ:RXST) Slips After Q2 Revenue Matches, Loss Narrows
↗
August 05, 2026
Via
Chartmill
RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction
↗
May 06, 2026
Via
Chartmill
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares
↗
February 25, 2026
Via
Chartmill
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
August 05, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
July 26, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
July 15, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
↗
July 10, 2026
RxSight (NASDAQ:RXST) reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with...
Via
MarketBeat
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
July 10, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
July 08, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
July 07, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
July 06, 2026
From
RxSight, Inc.
Via
GlobeNewswire
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
July 06, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
May 19, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight (RXST) Q1 2026 Earnings Transcript
↗
May 12, 2026
RxSight (RXST) Q1 2026 Earnings Transcript
Via
The Motley Fool
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
May 06, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight, Inc. to Present at the Bank of America Healthcare Conference
April 29, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
April 22, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 02, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight (RXST) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
RxSight (RXST) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
February 25, 2026
From
RxSight, Inc.
Via
GlobeNewswire
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 11, 2026
From
RxSight, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
January 11, 2026
From
RxSight, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
January 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
January 02, 2026
From
RxSight, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
December 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
